These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29675946)

  • 21. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
    Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
    Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
    Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
    CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
    Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.
    Harada T; Kikushige Y; Miyamoto T; Uno K; Niiro H; Kawakami A; Koga T; Akashi K; Yoshizaki K
    Nat Commun; 2023 Oct; 14(1):6959. PubMed ID: 37907518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased mTOR activation in idiopathic multicentric Castleman disease.
    Arenas DJ; Floess K; Kobrin D; Pai RL; Srkalovic MB; Tamakloe MA; Rasheed R; Ziglar J; Khor J; Parente SAT; Pierson SK; Martinez D; Wertheim GB; Kambayashi T; Baur J; Teachey DT; Fajgenbaum DC
    Blood; 2020 May; 135(19):1673-1684. PubMed ID: 32206779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
    Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
    Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
    Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
    Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
    Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
    Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
    Fajgenbaum DC; van Rhee F; Nabel CS
    Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.
    Shirakashi M; Nishida Y; Nakashima R; Fujimoto M; Hiwa R; Tsuji H; Kitagori K; Akizuki S; Morinobu A; Yoshifuji H
    Sci Rep; 2024 Feb; 14(1):2889. PubMed ID: 38311632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
    Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
    Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International definition of iMCD-TAFRO: future perspectives.
    Nishimura Y; Nishimura MF; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic basis for iMCD-TAFRO.
    Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
    Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.